A model of mptp-induced parkinson's disease in the goldfish

Nature Protocols

Volumn 2, Issue 11, 2007, Pages 3016-3021

  Weinreb, Orly ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ACCLIMATIZATION; ANIMAL; ARTICLE; BRAIN; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DISSECTION; DRUG EFFECT; GOLDFISH; HISTOLOGY; INTOXICATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACCLIMATIZATION; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DISSECTION; GOLDFISH; MPTP POISONING;

EID: 39149136909     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2007.393     Document Type: Article

References (39)

1. Hirsch, E.C. Biochemistry of Parkinson's disease with special reference to the dopaminergic systems. Mot. NeurobioL 9, 135-142 (1994).
2. Olanow, C.W. & Youdim, M.B. Iron and neurodegeneration: prospects for neuroprotection. in Neurodegeneration and Neuroprotection in Parkinson's Disease (eds. Olanow, C.W., Jenner, P. & Youdim, M.B.) 55-69 (Academic Press, London, 1996).
3. Jellinger, K.A. Post mortem studies in Parkinson's disease—is it possible to detect brain areas for specific symptoms? J. Neural Transm. Suppl. 1-29 (1991).
4. Jenner, P. & Olanow, C.W. Understanding cell death in Parkinson's disease. Ann. Neurol. 44 (3 Suppl 1): S72-S84 (1998).
5. Jenner, P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13 (Suppl 1): 24-34 (1998).
6. McNaught, K.S. & Jenner, P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297, 191-194 (2001).
7. Youdim, M.B., Ben-Shachar, D. & Riederer, P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand. Suppl. 126, 47-54 (1989).
8. Langston, J.W. & Ballard, P.A. Jr. Parkinson's disease in a chemist working with 1- methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. 309, 310 (1983).
9. Langston, J.W., Ballard, P., Tetrud, J.W. & Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980.
10. Burns, R.S. et at. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta ofthe substantia nigra by N-methyl- 4- phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80, 4546-4550 (1983).
11. Langston, J.W., Forno, L.S., Rebert, C.S. & Irwin, I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 292, 390-394 (1984).
12. Heikkila, R.E., Hess, A. & Duvoisin, R.C. Dopaminergic neurotoxicity of1-methyl- 4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224, 1451-1453 (1984).
13. Chiueh, C.C. et at. Neurochemical and behavioral effects of 1-methyl-4-phenyl-tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacot. Bull. 20, 548-553 (1984).
14. Schneider, J.S., Yuwiler, A. & Markham, C.H. Production of a Parkinson-like syndrome in the catwith N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior, histology, and biochemistry. Exp. Neurot. 91, 293-307 (1986).
15. McKinley, E.T. et al. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons. Brain Res. Mot. Brain Res. 141, 128-137 (2005).
16. Lam, C.S., Korzh, V. & Strahle, U. Zebrafish embryos are susceptible to the dopaminergic neurotoxin MPTP. Eur. J. Neurosci. 21, 1758-1762 (2005).
17. Poli, A., Guarnieri, T., Facchinetti, F. & Villani, L. Effect of 1-methyl-4-phenyl-tetrahydropyridine (MPTP) in goldfish brain. Brain Res. 534, 45-50 (1990).
18. Youdim, M.B. et al. MPTP-induced 'parkinsonism' in the goldfish. Neurochem. Int. 20 (Suppl.): 275S-278S (1992).
19. Pollard, H.B. et at. A parkinsonian syndrome induced in the goldfish by the neurotoxin MPTP. FASEBJ. 6, 3108-3116 (1992).
20. Lucchi, R. et at. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in goldfish cerebellum: neurochemical and immunocytochemical analysis. Brain Res. 782, 105-112 (1998).
21. Adams, J.D. Jr., Kalivas, P.W. & Miller, C.A. The acute histopathology of MPTP in the mouse CNS. Brain Res. Butt. 23, 1-17 (1989).
22. Hallman, H., Lange, J., Olson, L., Stromberg, I. & Jonsson, G. Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-tetrahydropyridine on brain catecholamine neurones in the mouse. J. Neurochem. 44, 117-127 (1985).
23. Heikkila, R.E., Manzino, L., Cabbat, F.S. & Duvoisin, R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467-469.
24. Uhl, G.R., Javitch, J.A. & Snyder, S.H. Normal MPTP binding in parkinsonian substantial nigra: evidence for extraneuronal toxin conversion in human brain. Lancet 1, 956-957 (1985).
25. Javitch, J.A., D'Amato, R.J., Strittmatter, S.M. & Snyder, S.H. Parkinsonism- inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82, 2173-2177.
26. Fritz, R.R., Abell, C.W., Patel, N.T., Gessner, W. & Brossi, A. Metabolism of the neurotoxin in MPTP by human liver monoamine oxidase B. FEBS Lett. 186, 224-228 (1985).
27. Bezard, E. et at. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurot. 155, 268-273 (1999).
28. Grunblatt, E., Mandel, S., Maor, G. & Youdim, M.B. Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal doamine neuronal loss. J. Neurochem. 77, 146-156 (2001).
29. Cohen, G. et at. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacot. 106, 209-210 (1984).
30. Pollard, H.B., Kuijpers, G.A., Adeyemo, O.M., Youdim, M.B. & Goping, G. The MPTP-induced parkinsonian syndrome in the goldfish is associated with major cell destruction in the forebrain and subtle changes in the optic tectum. Exp. Neurot. 142, 170-178 (1996).
31. Adeyemo, O.M., Youdim, M.B., Markey, S.P., Markey, C.J. & Pollard, H.B. L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish. Eur. J. Pharmacot. 240, 185-193 (1993).
32. Sagi, Y., Mandel, S., Amit, T. & Youdim, M.B. Activation oftyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiot. Dis. 25, 35-44 (2007).
33. Hornby, P.J. & Piekut, D.T. Distribution ofcatecholamine-synthesizingenzymesin goldfish brains: presumptive dopamine and norepinephrine neuronal organization. Brain Behav. Evot. 35, 49-64 (1990).
34. Watson, A.H. The distribution ofaminergic neurones and their projections in the brain of the teleost, Myoxocephatus scorpius. Celt Tissue Res. 208, 299-312 (1980).
35. Goping, G., Pollard, H.B., Adeyemo, O.M. & Kuijpers, G.A. Effect of MPTP on dopaminergic neurons in the goldfish brain: a light and electron microscope study. Brain Res. 687, 35-52 (1995).
36. Hibbert, B. et at. Increased GAD67 mRNA levels are correlated with in vivo GABA synthesis in the MPTP-treated catecholamine-depleted goldfish brain. Brain Res. Mot. Brain Res. 128, 121-130 (2004).
37. Przedborski, S. et at. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76, 1265-1274 (2001).
38. Yang, S.C., Markey, S.P., Bankiewicz, K.S., London, W.T. & Lunn, G. Recommended afe practices for using the neurotoxin MPTP in animal experiments. Lab Anim. Sci. 38, 563-567 (1988).
39. Weissman, J. et at. Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-tetrahydropyridine by liver homogenate fractions. J. Med. Chem. 28, 997-1001 (1985).